Stelexis Therapeutics Closes $43 million Series A to Expand Novel Platform Focused on Cancer Interception
Mark Cohen, Senior Partner and Chair of the Life Science Practice Group represents Stelexis Therapeutics in intellectual property and commercial matters.
For the full article, click HERE
